| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis |
|
Medicine details |
|
| Medicine name | colistimethate sodium (Colobreathe®) |
| Formulation | inhalation powder |
| Reference number | 612 |
| Indication | Management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older |
| Company | Forest Laboratories UK Ltd |
| BNF chapter | Infections |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/10/2011 |
| NICE guidance | |